Mantle Cell Lymphoma | Specialty

Dr. Brody on Managing CAR T-Cell Therapy Toxicities in MCL

November 25th 2020

Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.

CAR T-Cell Therapy Creates Opportunities for Individualized Treatment in MCL

November 24th 2020

Alan P. Z. Skarbnik, MD, highlights how treatment decisions in mantle cell lymphoma have become more nuanced since the FDA approval of the CAR T-cell therapy brexucabtagene autoleucel in the relapsed/refractory setting.

Dr. Ruan on Treatment Considerations in MCL

November 23rd 2020

Jia Ruan, MD, PhD, discusses treatment considerations in mantle cell lymphoma.

Dr. Skarbnik on Current Treatment Strategies Making Waves in MCL

November 19th 2020

Alan P. Z. Skarbnik, MD, discusses treatment strategies for patients with mantle cell lymphoma.

CAR T-Cell Combinations May Offer a Way to Overcome Antigen Escape in MCL

November 19th 2020

Joshua Brody, MD, discusses advances made with CAR T-cell therapy in MCL, the promise of venetoclax in B-cell malignancies, and the potential for bispecific antibody combination regimens in this disease.

Dr. Brody on the Potential Role for Bispecific Antibodies in MCL

November 18th 2020

Joshua Brody, MD, discusses the potential role for bispecific antibodies in mantle cell lymphoma.

Dr. Ruan on the Evolving Armamentarium in MCL

November 16th 2020

Jia Ruan, MD, PhD, discusses the evolving armamentarium ​in mantle cell lymphoma.

Dr. Brody on the Challenges of Antigen Escape in MCL

November 12th 2020

Joshua Brody, MD, discusses the challenges of mitigating antigen escape in mantle cell lymphoma.

Dr. Ruan on the Incidence of MCL

November 10th 2020

Jia Ruan, MD, PhD, discusses the incidence of mantle cell lymphoma.

Dr. Skarbnik on the Approval of Brexucabtagene Autoleucel in MCL

November 9th 2020

Alan P. Z. Skarbnik, MD, discusses the approval of brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.

x